<DOC>
	<DOC>NCT02951975</DOC>
	<brief_summary>This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.</brief_summary>
	<brief_title>Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient with noninfectious uveitis affecting the posterior segment of the eye. Patient not residing in metropolitan France.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>